17 April 2014, 4:00 pm
A new experimental NS5A inhibitor, GS-5816, was shown to be safe and effective when used in an interferon- and ribavirin-free dual regimen with sofosbuvir (Sovaldi) for people with hepatitis C genotypes 1 through 6, according to phase 2 trial results presented at the 49th annual meeting of the European Association for the Study of

17 April 2014, 1:00 pm
 'Chem sex' (taking recreational drugs during sex) and attendance at sex parties are commonly reported by UK gay men with shigella infection, according to research presented to the recent Joint Conference of BHIVA (British HIV Association) with BASHH (British Association for Sexual Health and HIV). Investigators interviewed 42 men recently diagnosed with shigella. Overall, three-quarters

17 April 2014, 8:00 am
A combination of two direct-acting antivirals developed by Bristol-Myers Squibb (BMS) cured 90% of previously untreated people with genotype 1b hepatitis C infection in 24 weeks, without the need for pegylated interferon or ribavirin, Prof. Michael Manns of Hannover Medical School, Germany, reported at the 49th Annual Meeting of the European Association for the

16 April 2014, 5:00 pm
Sofosbuvir plus ribavirin is a safe option that can lead to sustained response in people with advanced liver disease including those with decompensated cirrhosis and portal hypertension, and people who experience severe hepatitis recurrence after a liver transplant, researchers reported last week at the 49th Annual Meeting of the European Association for the Study of

16 April 2014, 12:00 pm
The achievement of universal HIV coverage in one African country, Rwanda, has resulted in HIV diagnoses more than halving and annual incidence falling by 90%, the 2014 Treatment as Prevention workshop in Vancouver heard earlier this month. Edward Mills of the British Columbia Centre for Excellence in HIV/AIDS, which runs a clinic in Rwanda, told

1 2

    • No upcoming events
  • View All Add your news